Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Otilimab - GlaxoSmithKline

Drug Profile

Otilimab - GlaxoSmithKline

Alternative Names: GSK-3196165; GSK165; MOR-103

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer GlaxoSmithKline; MorphoSys
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis
  • Phase II Severe acute respiratory syndrome
  • No development reported Inflammation
  • Discontinued Multiple sclerosis; Osteoarthritis

Most Recent Events

  • 24 Jun 2020 GlaxoSmithKline re-initiates enrolment in its previously-suspended phase III contRAst-3 trial in Rheumatoid arthritis (Combination therapy, Treatment-experienced) in the US, Argentina, Belgium, Canada, Czech Republic, Hungary, Italy, Japan, South Korea, South Africa, Poland, Lithuania, Spain and United Kingdom (NCT04134728) (EudraCT2019-000868-18)
  • 24 Jun 2020 GlaxoSmithKline re-initiates enrolment in its previously suspended phase III contRAst-1 trial in Rheumatoid arthritis (Combination therapy, Treatment-experienced) in the US, Argentina, Canada, Czech Republic, Hungary, India, Italy, Latvia, Lithuania, Malaysia, Poland, Russia, South Africa, Spain, Ukraine and United Kingdom (SC) (NCT03980483) (EudraCT2019-000797-39)
  • 22 Jun 2020 GlaxoSmithKline re initiates the phase III contRAst-2 trial in Rheumatoid arthritis in the US, Argentina, Bulgaria, Colombia, Estonia, France, Hungary, Japan, South Korea, Poland, Russia, Spain, Germany, Australia and United Kingdom (NCT03970837) (EudraCT2019-000867-26)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top